Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1301 to 1310 of 1856 total matches.

Mumps Outbreak

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014  (Issue 1438)
and older students at risk of exposure, vaccination consists of 2 doses of MMR vaccine at least 28 days ...
An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
Med Lett Drugs Ther. 2014 Mar 17;56(1438):21 |  Show IntroductionHide Introduction

In Brief: Enteric-Coated Aspirin as an Antiplatelet Drug

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2014  (Issue 1441)
activation and aggregation for the life of the platelet (5-7 days). Aspirin prophylaxis reduces ...
One of our readers has suggested that more attention should have been paid to a study comparing the antiplatelet effects of immediate-release and enteric-coated aspirin that appeared in Circulation last year.1 The safety benefits of enteric-coated aspirin are unclear. It may protect against dyspepsia, but not against major gastrointestinal bleeding, which is thought to be mainly a systemic effect of prostaglandin inhibition.ANTIPLATELET EFFECTS OF ASPIRIN — Aspirin irreversibly acetylates cyclooxygenase-1, blocking thromboxane synthesis and inhibiting platelet activation and aggregation for...
Med Lett Drugs Ther. 2014 Apr 28;56(1441):36 |  Show IntroductionHide Introduction

In Brief: Concerns about Oseltamivir (Tamiflu)

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2015  (Issue 1460)
shorten the duration of symptoms by about one day. Most controlled trials of the effectiveness ...
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk patients with confirmed or suspected influenza illness, citing the British Medical Journal and The Cochrane Collaboration, which have contended that there is no acceptable evidence that the drug prevents complications or hospitalizations and have questioned the completeness of the results of controlled trials conducted by the manufacturer (Roche).
Med Lett Drugs Ther. 2015 Jan 19;57(1460):14 |  Show IntroductionHide Introduction

In Brief: A New Formulation of Posaconazole (Noxafil)

   
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015  (Issue 1461)
vials. The recommended dosage is 300 mg administered intravenously over 90 minutes twice on day 1 ...
The FDA has approved an IV formulation of the antifungal drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults at high risk for these infections, such as those with prolonged neutropenia. Posaconazole is also available as delayed-release tablets and an oral suspension.With activity against Aspergillus and Candida, posaconazole has an antifungal spectrum similar to that of voriconazole (Vfend, and generics), but unlike voriconazole it is also active against many species of Mucorales (formerly called Zygomycetes), such as Mucor and Rhizopus....
Med Lett Drugs Ther. 2015 Feb 2;57(1461):20 |  Show IntroductionHide Introduction

In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015  (Issue 1466)
2-12 days in 3 others. One patient died of cardiac arrest and 3 required pacemaker implantation ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...
Med Lett Drugs Ther. 2015 Apr 13;57(1466):58 |  Show IntroductionHide Introduction

In Brief: Acalabrutinib (Calquence) for Mantle Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
comparing acalabrutinib with ibrutinib are available to date. The cost of 30 days’ treatment ...
The FDA has approved the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence – AstraZeneca) for oral treatment of relapsed or refractory mantle cell lymphoma. Acalabrutinib is the second BTK inhibitor to be approved for this indication; ibrutinib (Imbruvica) was approved in 2013.Ibrutinib inhibits other kinases in addition to BTK and has been associated with severe adverse effects, particularly atrial fibrillation, infection, rash, and bleeding, that may be related to inhibition of kinases other than BTK.1 Acalabrutinib is a more selective BTK inhibitor than ibrutinib; whether...
Med Lett Drugs Ther. 2018 Nov 5;60(1559):e184 |  Show IntroductionHide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
of COVID-19 with onset ≥7 days after the second dose among SARS-CoV-2-naive subjects who received ...
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Med Lett Drugs Ther. 2021 May 31;63(1625):81 |  Show IntroductionHide Introduction

In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
occurred within 42 days of vaccination; 95 of the 100 persons who developed GBS required hospitalization ...
On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following administration of the product.
Med Lett Drugs Ther. 2021 Aug 9;63(1630):121 |  Show IntroductionHide Introduction

In Brief: Merilog — A NovoLog Biosimilar

   
The Medical Letter on Drugs and Therapeutics • Mar 11, 2025  (Issue 5101)
negotiated rate for a 30-day supply of NovoLog is $119. 1. SK Garg et al. Efficacy and safety of insulin ...
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog), for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
Med Lett Drugs Ther. 2025 Mar 11;67(5101):1   doi:10.58347/tml.2025.5101a |  Show IntroductionHide Introduction

In Brief: A Home Test for Chlamydia, Gonorrhea, and Trichomoniasis

   
The Medical Letter on Drugs and Therapeutics • May 12, 2025  (Issue 1728)
about 3-5 days for results to be delivered, which could delay treatment.1 Individuals who ...
The FDA has authorized use of the Visby Medical Women's Sexual Health Test (Visby), an at-home test available without a prescription, for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis infections in women with and without symptoms. It is the first test to become available in the US for these sexually transmitted infections (STIs) that can be performed entirely at home. Other at-home tests are available in the US for diagnosis of chlamydia, gonorrhea, and trichomoniaisis, but they require mailing a urine or blood sample to a...
Med Lett Drugs Ther. 2025 May 12;67(1728):80   doi:10.58347/tml.2025.1728e |  Show IntroductionHide Introduction